You are here

  • Home
  • Online First
  • Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma

Article info

Article menu
Download PDFPDF
Clinical science
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma

Authors

  • Jacob Sterling Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, USAMedical Scientist Training Program, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Peiying Hua Center for Preventative Ophthalmology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Joshua L Dunaief Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Qi N Cui Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Brian L VanderBeek Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania, USACenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics & Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USALeonard Davis Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Brian L VanderBeek, Department of Ophthalmology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; brian.vanderbeek{at}pennmedicine.upenn.edu
View Full Text

Citation

Sterling J, Hua P, Dunaief JL, et al
Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma
British Journal of Ophthalmology Published Online First: 19 August 2021. doi: 10.1136/bjophthalmol-2021-319232

Publication history

  • Received March 10, 2021
  • Accepted August 6, 2021
  • First published August 19, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.